Inmune Bio (INMB) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Inmune Bio (INMB) over the last 5 years, with Q3 2025 value amounting to -$0.24.
- Inmune Bio's EPS (Weighted Average and Diluted) rose 6000.0% to -$0.24 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.12, marking a year-over-year increase of 275.23%. This contributed to the annual value of -$2.14 for FY2024, which is 2800.62% down from last year.
- Latest data reveals that Inmune Bio reported EPS (Weighted Average and Diluted) of -$0.24 as of Q3 2025, which was up 6000.0% from -$1.05 recorded in Q2 2025.
- Inmune Bio's EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.24 during Q3 2025, with a 5-year trough of -$1.05 in Q2 2025.
- For the 5-year period, Inmune Bio's EPS (Weighted Average and Diluted) averaged around -$0.48, with its median value being -$0.47 (2023).
- Within the past 5 years, the most significant YoY rise in Inmune Bio's EPS (Weighted Average and Diluted) was 6000.0% (2025), while the steepest drop was 11000.0% (2025).
- Quarter analysis of 5 years shows Inmune Bio's EPS (Weighted Average and Diluted) stood at -$0.56 in 2021, then soared by 43.78% to -$0.31 in 2022, then crashed by 49.34% to -$0.47 in 2023, then dropped by 0.99% to -$0.47 in 2024, then soared by 49.44% to -$0.24 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.24 in Q3 2025, compared to -$1.05 in Q2 2025 and -$0.43 in Q1 2025.